The GSTK1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of A-549 lung adenocarcinoma cells in which the GSTK1 gene has been disrupted. This knockout model is generated using CRISPR/Cas9-mediated gene targeting, producing a heterogeneous pool of cells with loss-of-function mutations in GSTK1. As a polyclonal population, it reflects the diversity of editing outcomes without clonal selection, making it suitable for bulk functional studies. The cells provide a genetically defined system to investigate the role of mitochondrial glutathione transferase in cellular detoxification and antioxidant responses.
The host A-549 cell line is an established adherent epithelial model derived from the lung adenocarcinoma of a 58-year-old male. These cells exhibit characteristics of alveolar type II epithelial cells and are widely employed in respiratory disease research, including studies of drug resistance, xenobiotic metabolism, and oxidative stress. The A-549 background retains key signaling pathways relevant to lung cancer biology, making it an appropriate context for examining the impact of GSTK1 knockout on mitochondrial redox homeostasis and chemosensitivity.
GSTK1 is a mitochondrial glutathione transferase that conjugates reduced glutathione (GSH) to electrophilic substrates, enabling detoxification and protecting mitochondria from oxidative damage. Its expression is upregulated by the NFE2L2 (Nrf2) transcription factor and the aryl hydrocarbon receptor (AHR) in response to oxidative or xenobiotic stress. By modulating reactive oxygen species (ROS) levels and mitochondrial membrane potential, GSTK1 influences apoptotic sensitivity. It operates within the glutathione metabolism network, interacting with GSH synthesis enzymes and other GST family members as part of the Nrf2-Keap1 antioxidant axis.
Disruption of GSTK1 in A-549 cells abolishes a vital mitochondrial detoxification pathway, leading to increased accumulation of electrophilic species and elevated oxidative stress. This genetic perturbation is expected to sensitize cells to chemotherapeutic agents, particularly those inducing mitochondrial dysfunction or ROS production, reflecting the gene’s role in drug resistance. The knockout model recapitulates loss-of-function scenarios observed in certain oxidative stress-related pathologies and provides a platform to study the mitochondrial consequences of impaired glutathione conjugation. In the context of lung adenocarcinoma, the GSTK1 knockout A-549 cells enable dissection of mechanisms by which cancer cells evade oxidative damage and develop resistance to therapies, potentially identifying targets for chemosensitization.
This knockout model supports a broad range of functional studies, including glutathione S-transferase activity assays, ROS detection, mitochondrial membrane potential measurement, and apoptosis analysis. Typical applications encompass screening for chemosensitizers, investigating mitochondrial GST function in drug resistance, and exploring oxidative stress biology. For additional information or technical support, please contact Ascent Research.
